Publications
2020
. The preclinical characterization and development of EPI-7386, an N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer. [Poster Session]. American Urology Association Annual Conference, Washington, DC, United States.
Read More > 2020 American Urology Association Annual Conference Poster. IND Candidate EPI-7386 as an N-terminal Domain Androgen Receptor Inhibitor in Development for the Treatment of Prostate Cancer. American Society of Clinical Oncology Genitourinary Cancers Symposium 2020. (Abstract ID #142).
Read More > 2020 Genitourinary Cancers Symposium Poster
2019
. Treatment of castrated resistant prostate cancer, with EPI-7386, a second generation N-terminal domain androgen receptor inhibitor. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. (Abstract ID B117).
Read More > AACR-NCI-EORTC Poster. Treatment of castrated resistant prostate cancer, with EPI-7386, a second generation N-terminal domain androgen receptor inhibitor. The 26th Annual Scientific Retreat | Prostate Cancer Foundation.
Read More > Prostate Cancer Foundation Annual Retreat Poster. EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer. European Society of Medical Oncology (ESMO) 2019 Congress. (Abstract ID 503P).
Read More > European Society of Medical Oncology 2019 Congress Poster